Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.4 (Exhibit EX-99.4), Item 7.01 (Regulation FD Disclosure). Webster affiliates to acquire Lifecore for $6.28 cash per common share plus one non-tradeable CVR.
LIFECORE BIOMEDICAL, INC. DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Webster affiliates to acquire Lifecore for $6.28 cash per common share plus one non-tradeable CVR
- CVRs could pay $30M in 2028, $45M in 2029, and $85M in 2030, contingent on revenue and EBITDA milestones
- Financing includes $400M equity, $115M term loans, $30M revolver, and $35M Alcon term loan
- Closing requires stockholder approval, HSR clearance, continued Alcon agreements, and no continuing material adverse effect
- Company stock will be delisted from Nasdaq and deregistered if the merger closes; termination fees range from $7.47M to $16.18M
Item 7.01 · Regulation FD Disclosure
- Merger Agreement announcement with Webster, signaling a proposed strategic transaction requiring investor review
- Employee communications include management presentation and CEO remarks on the proposed merger
- Press release, presentation, email and transcript provide transaction context beyond the filing summary
Item EX-99.1 · Exhibit EX-99.1
- Webster Equity Partners acquisition offers $6.28 per common share, a 49.5% premium to September 25, 2026’s closing price
- CVRs could add up to $160 million, raising potential consideration to $9.67 per common equivalent
- Series A preferred holders receive approximately $50.2 million conversion value as of June 30, 2026, plus 7.5% annual PIK dividends through closing
- Closing targeted for fourth-quarter 2026, subject to stockholder and regulatory approvals
- Nasdaq delisting expected after closing, with a 30-day go-shop period creating potential for competing bids
Item EX-99.2 · Exhibit EX-99.2
- Webster Equity Partners acquisition values Lifecore at up to approximately $663.7 million
- Cash consideration of $6.28 per share at closing
- Additional potential cash payments of $3.39 per share, tied to 2028-2030 milestones and $160 million aggregate maximum payments
- Closing expected at end of Q4 2026, subject to stockholder and regulatory approvals
- Completion would end Lifecore’s public reporting and public trading status
Item EX-99.3 · Exhibit EX-99.3
- Webster Equity Partners affiliate to acquire Lifecore for $6.28 per share in cash plus one contingent value right
- Expected closing end of Q4 2026, subject to stockholder and regulatory approvals
- Transaction converts Lifecore into a private company while retaining the Lifecore name and Chaska headquarters
- Unanimously approved by the transaction committee and board, supporting deal certainty but not eliminating closing risks
- Go-shop period begins immediately, creating potential for competing offers before stockholder approval
Item EX-99.4 · Exhibit EX-99.4
- Webster Equity Partners affiliate acquisition: $6.28 per share in cash, plus CVRs worth up to $160 million aggregate
- Lifecore becomes privately held and delisted at closing, currently expected end of fourth quarter 2026
- 30-day go-shop period creates potential for competing superior offers before stockholder and regulatory approvals
- Three-year Alcon manufacturing agreement extension through 2034 strengthens commercial visibility and supports post-transaction growth
- CVR payments depend on 2028, 2029 and 2030 performance milestones, creating uncertain additional shareholder value
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIFECORE BIOMEDICAL, INC. DE 8-K filings
Get the next LFCR 8-K as it lands
Follow LFCR for push alerts, or ask the research agent what this filing means.